重组人干扰素α1b联合布地奈德对毛细支气管炎患儿炎症反应的影响

Effect of Recombinant Human Interferon α 1b Combined with Budesonide on Inflammatory Response in Children with Bronchiolitis

目的探究重组人干扰素α1b联合布地奈德对毛细支气管炎患儿炎症反应的影响.方法选取2021年4月—2022年5月我院收治的94例毛细支气管炎患儿为研究对象,按随机数字表法分为对照组及观察组,每组47例.对照组采用布地奈德治疗,观察组在此基础上采用重组人干扰素α1b治疗,两组均治疗7 d.比较两组的临床疗效、炎症反应、症状消失时间、肺功能及不良反应发生情况.结果观察组的治疗总有效率为97.87%,高于对照组的82.97%,差异有统计学意义(P<0.05).治疗后,观察组的白细胞介素-18、C反应蛋白、肿瘤坏死因子-α水平分别为(142.34±16.49)ng/L、(4.17±0.88)mg/L、(18.64±12.85)μg/mL,均低于对照组的(166.45±18.13)ng/L、(5.44±1.26)mg/L、(27.22±13.46)μg/mL,干扰素-γ水平为(118.37±18.25)mg/L,高于对照组的(107.38±15.19)mg/L,组间差异有统计学意义(P<0.05).观察组的咳嗽、喘息、肺部啰音、三凹症消失时间分别为(4.21±0.45)d、(3.69±1.02)d、(4.74±0.51)d、(2.98±0.47)d,均短于对照组的(5.68±0.53)d、(4.15±0.96)d、(5.28±0.74)d、(4.12±0.62)d,组间差异有统计学意义(P<0.05).治疗后,观察组的潮气量、最大通气量、呼气峰流速水平分别为(7.51±1.62)mL/kg、(93.35±5.31)L/min、(151.03±20.49)L/min,均高于对照组的(6.45±1.44)mL/kg、(89.49±5.23)L/min、(142.66±16.42)L/min,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论采用重组人干扰素α1b联合布地奈德治疗小儿毛细支气管炎的效果确切,可减轻炎症反应,缩短症状消失时间,改善肺功能,安全可靠,临床应用价值高,值得推广.

Objective To investigate the effect of recombinant human interferonα1b combined with budesonide on inflammation in children with bronchiolitis.Methods A total of 94 children with bronchiolitis admitted to our hospital from April 2021 to May 2022 were selected as research objects,and were divided into a control group and an observation group according to random number table method,with 47 cases in each group.The control group was treated with budesonide,and the observation group was treated with recombinant human interferonα1b,both groups were treated for 7 days.The clinical efficacy,inflammatory reaction,time of symptom disappearance,lung function and occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.87%,which was higher than 82.97%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of interleukin-18,C-reactive protein and tumor necrosis factor-αin the observation group were(142.34±16.49)ng/L,(4.17±0.88)mg/L,(18.64±12.85)μg/mL,respectively,which were lower than(166.45±18.13)ng/L,(5.44±1.26)mg/L and(27.22±13.46)μg/mL in the control group,the level of interferon-γwas(118.37±18.25)mg/L,which was higher than(107.38±15.19)mg/L in the control group,the differences between the groups were statistically significant(P<0.05).In the observation group,the disappearance time of cough,wheezing,pulmonary rale and trichosa were(4.21±0.45)d,(3.69±1.02)d,(4.74±0.51)d,(2.98±0.47)d,respectively,which were shorter than(5.68±0.53)d,(4.15±0.96)d,(5.28±0.74)d and(4.12±0.62)d in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the tidal volume,maximal voluntary ventilation and peak expiratory flow of the observation group were(7.51±1.62)mL/kg,(93.35±5.31)L/min and(151.03±20.49)L/min,respectively,which were higher than(6.45±1.44)mL/kg,(89.49±5.23)L/min and(142.66±16.42)L/min in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant human interferonα1b combined with budesonide in the treatment of bronchiolitis in children is effective,can reduce inflammation,shorten the time of symptom disappearance,improve lung function,is safe and reliable,and has high clinical application value,which is worthy of promotion.